NCT02484053View on ClinicalTrials.gov

Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Hematologic DisordersOncologic DisordersRheumatologic Disorders
Interventions
DRUG

Rituximab

Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.

Trial Locations (1)

77030

Texas Children's Hospital, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT02484053 - Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders | Biotech Hunter | Biotech Hunter